Atlas Trials

Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma

Clinical trial NCT02237261 · COMPLETED

Trial details

NCT number
NCT02237261
Sponsor
University Hospital Heidelberg
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2014-11-01
Primary completion
2018-10-01
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.